Mural Oncology plc (NASDAQ:MURA - Get Free Report) CFO Adam D. Cutler sold 7,421 shares of the stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $3.41, for a total value of $25,305.61. Following the transaction, the chief financial officer now owns 71,438 shares of the company's stock, valued at approximately $243,603.58. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Mural Oncology Price Performance
Shares of NASDAQ MURA opened at $3.46 on Friday. The stock has a market capitalization of $58.95 million and a price-to-earnings ratio of -0.33. The business has a 50-day moving average of $3.34 and a 200-day moving average of $3.40. Mural Oncology plc has a fifty-two week low of $2.88 and a fifty-two week high of $17.00.
Mural Oncology (NASDAQ:MURA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($1.86) earnings per share for the quarter, beating the consensus estimate of ($1.90) by $0.04. On average, sell-side analysts expect that Mural Oncology plc will post -7.59 EPS for the current year.
Analysts Set New Price Targets
Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction
From Paradigm Press | Ad
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs…
A predicted Trump would win.
You won’t believe what he’s predicting now.
Click here to see it because it’s a SHOCKER…
A number of equities analysts have issued reports on MURA shares. Raymond James started coverage on Mural Oncology in a report on Friday, October 4th. They set a "strong-buy" rating and a $18.00 target price for the company. HC Wainwright started coverage on Mural Oncology in a report on Thursday, October 17th. They set a "buy" rating and a $18.00 target price for the company.
Check Out Our Latest Stock Analysis on MURA
Institutional Investors Weigh In On Mural Oncology
Several hedge funds have recently bought and sold shares of MURA. Harbor Capital Advisors Inc. acquired a new stake in Mural Oncology in the 2nd quarter valued at about $115,000. Rhumbline Advisers acquired a new stake in Mural Oncology in the 2nd quarter valued at about $34,000. BBR Partners LLC acquired a new stake in Mural Oncology in the 2nd quarter valued at about $31,000. Acadian Asset Management LLC acquired a new stake in Mural Oncology during the second quarter worth approximately $998,000. Finally, Nicollet Investment Management Inc. acquired a new stake in Mural Oncology during the second quarter worth approximately $308,000. 80.21% of the stock is currently owned by institutional investors and hedge funds.
Mural Oncology Company Profile
(
Get Free Report)
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
